Characteristics, Genetic Testing, and Diagnoses of Infants with Neonatal Encephalopathy Not Due to Hypoxic Ischemic Encephalopathy: A Cohort Study.
Characteristics, Genetic Testing, and Diagnoses of Infants with Neonatal Encephalopathy Not Due to Hypoxic Ischemic Encephalopathy: A Cohort Study.
复制标题
非缺氧缺血性脑病所致新生儿脑病婴儿的特征、基因检测和诊断:队列研究。
DOI:
10.1016/j.jpeds.2023.113533
复制
发表时间:
2023
期刊:
影响因子:
--
通讯作者:
Law,JanessaB
中科院分区:
文献类型:
--
作者:
Lenahan,Arthur;Mietzsch,Ulrike;Wood,ThomasR;Callahan,KatharinePress;Weiss,ElliottM;Miller,DannyE;German,Kendell;Natarajan,Niranjana;Puia-Dumitrescu,Mihai;Esposito,Valentine;Kolnik,Sarah;Law,JanessaB
ObjectiveTo characterize the presentation and evaluation of infants with neonatal encephalopathy (NE) not due to hypoxic-ischemic encephalopathy (non-HIE NE) and to describe the genetic abnormalities identified.Study designRetrospective cohort study of 193 non-HIE NE neonates admitted to a level IV NICU from 2015 through 2019. For changes in testing over time, Cochrane-Armitage test for trend was used with a Bonferroni-correctedP-value, and comparison between groups was performed using Fisher exact test.ResultThe most common symptom of non-HIE NE was abnormal tone in 47% (90/193). Ten percent (19/193) died prior to discharge, and 48% of survivors (83/174) required medical equipment at discharge. Forty percent (77/193) underwent genetic testing as an inpatient. Of 52 chromosomal studies, 54 targeted tests, and 16 exome sequences, 10%, 41%, and 69% were diagnostic, respectively, with no difference in diagnostic rates between infants with and without an associated congenital anomaly and/or dysmorphic feature. Twenty-eight genetic diagnoses were identified.ConclusionsNeonates with non-HIE NE have high rates of morbidity and mortality and may benefit from early genetic testing, even in the absence of other exam findings. This study broadens our knowledge of genetic conditions underlying non-HIE NE, which may enable families and care teams to anticipate the needs of the individual, allow early initiation of targeted therapies, and facilitate decisions surrounding goals of care.